TY - CHAP A1 - Bryon A. Tompkins A2 - Ana Marie Landin A3 - Victoria Florea A4 - Makoto Natsumeda A5 - Angela C. Rieger A6 - Wayne Balkan A7 - Ivonne Hernandez Schulman A8 - Joshua M. Hare ED1 - Yannis Dionyssiotis Y1 - 2017-08-30 PY - 2017 T1 - Allogeneic Mesenchymal Stem Cells as a Treatment for Aging Frailty N2 - Frailty is considered a multisystem impairment that makes an individual vulnerable to external or internal stressors. Sarcopenia, the age-dependent loss of muscle mass and function, is proposed as the biological substrate and the pathway whereby the consequences of physical frailty develop. These syndromes are associated with a negative impact in quality of life and can lead to the occurrence of disability, institutionalization, and even mortality. The book focuses upon all the related aspects of frailty and sarcopenia and the new advancements in the related treatments including complex issues and research. It includes high-quality chapters in all related aspects for the syndromes of sarcopenia and frailty, which adversely affect the function and overall effectiveness of the musculoskeletal system and interventions to promote rehabilitation. BT - Frailty and Sarcopenia SP - Ch. 11 UR - https://doi.org/10.5772/intechopen.69194 DO - 10.5772/intechopen.69194 SN - 978-953-51-3484-8 PB - IntechOpen CY - Rijeka Y2 - 2020-08-12 ER -